The Current Ratio as of December 2024 (TTM) for BELLUS Health Inc. (BLU) is 1.50

According to BELLUS Health Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.50. This represents a change of -89.78% compared to the average of 14.71 of the last 4 quarters.

BELLUS Health Inc. (BLU) Historical Current Ratio (quarterly & annually)

How has BLU Current Ratio performed in the past?

The mean historical Current Ratio of BELLUS Health Inc. over the last ten years is 11.73. The current 1.50 Current Ratio has changed 1.18% with respect to the historical average. Over the past ten years (40 quarters), BLU's Current Ratio was at its highest in in the March 2023 quarter at 33.42. The Current Ratio was at its lowest in in the June 2023 quarter at 1.50.

BELLUS Health Inc. (BLU) Current Ratio by Quarter and Year

Discovering the peaks and valleys of BELLUS Health Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BELLUS Health Inc. (BLU) Average Current Ratio

How has BLU Current Ratio performed in the past?

The current Current Ratio of BELLUS Health Inc. (BLU) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

BELLUS Health Inc. (BLU) Current Ratio vs. Peers

How is BLU’s Current Ratio compared to its peers?

BELLUS Health Inc.’s Current Ratio is less than Terns Pharmaceuticals, Inc. (32.99), less than Amylyx Pharmaceuticals, Inc. (4.55), less than Acumen Pharmaceuticals, Inc. (10.43), less than Inozyme Pharma, Inc. (7.68), less than X4 Pharmaceuticals, Inc. (4.89), less than KalVista Pharmaceuticals, Inc. (6.87), less than Crinetics Pharmaceuticals, Inc. (16.38), less than Theseus Pharmaceuticals, Inc. (29.93), less than Kura Oncology, Inc. (11.47), less than Viridian Therapeutics, Inc. (18.55), less than Biomea Fusion, Inc. (0), less than Stoke Therapeutics, Inc. (3.39), less than Akero Therapeutics, Inc. (5.09), less than Homology Medicines, Inc. (17.25), less than Gossamer Bio, Inc. (4.19), less than Cytokinetics, Incorporated (6.74), less than DICE Therapeutics, Inc. (9.28), less than Edgewise Therapeutics, Inc. (38.14), less than Karuna Therapeutics, Inc. (26.35), less than Dyne Therapeutics, Inc. (19.31), less than null (17.02),

Build a custom stock screener for BELLUS Health Inc. (BLU) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BELLUS Health Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BELLUS Health Inc. (BLU) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BELLUS Health Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.